Welcome to our dedicated page for Amedisys news (Ticker: AMED), a resource for investors and traders seeking the latest updates and insights on Amedisys stock.
Amedisys Inc. (NASDAQ: AMED) is a leading healthcare services company in the United States, specializing in delivering personalized home health, hospice, and high-acuity care services. Headquartered in Baton Rouge, LA, with an executive office in Nashville, TN, the company employs around 18,700 staff across 520 care centers in 37 states and the District of Columbia. Founded in 1982, Amedisys is dedicated to providing quality, clinically-distinctive care to more than 469,000 patients annually, with over 10.6 million visits each year.
Amedisys operates across four key segments: Home Health, Hospice, High Acuity Care, and Personal Care. The Home Health segment offers skilled nursing, therapy, and aid services directly in patients' homes, while the Hospice segment provides end-of-life care to terminally ill patients. The High Acuity Care segment delivers critical inpatient care elements at home, and the Personal Care segment, which was divested in March 2023, offered assistance with daily living activities.
Amedisys's commitment to high-quality care is underpinned by its comprehensive coordination with healthcare providers and personalized care plans tailored to each patient's unique needs. With a strong network involving more than 3,000 hospitals and 110,000 physicians nationwide, Amedisys is a trusted partner in post-acute care.
Recent notable achievements include a merger agreement with UnitedHealth Group, aimed at enhancing patient care through integrated services. Financially, Amedisys reported a net service revenue increase to $571.4 million for Q1 2024, reflecting a robust service demand despite divesting the Personal Care segment.
Additionally, Amedisys is actively involved in advancing healthcare technology. The company has partnered with Patient Choice Laboratories to incorporate advanced molecular testing, enhancing infection diagnosis and patient outcomes. This innovation underscores Amedisys’s commitment to leveraging cutting-edge technology to improve patient care.
For stakeholders, Amedisys remains a prominent figure in the home healthcare industry, constantly adapting and growing to meet the increasing needs of its patient population. The company's strategic partnerships and advancements in healthcare technology position it well for sustained growth and improved patient outcomes.
Amedisys, Inc. (AMED) has signed a definitive agreement to acquire Evolution Health, LLC, enhancing its home health services. The acquisition, expected to close in the first half of 2022, will allow Amedisys to serve over 1.9 million Medicare enrollees in Texas and over 800,000 in Ohio, increasing its network to 346 care centers across 34 states. This move aims to strengthen Amedisys' position as a quality home healthcare provider, expanding patient access and aligning with existing hospice services.
Amedisys, Inc. (NASDAQ: AMED) will report its fourth quarter and full year results for 2021 on February 23, 2022, after market close. An investor conference call is scheduled for February 24, 2022, at 11:00 a.m. ET. Participants can join by dialing (877) 524-8416 or (412) 902-1028. A replay will be available until March 24, 2022. A live webcast will also be accessible on the Company's Investor Relations website. Amedisys focuses on delivering personalized home health, hospice, personal care, and higher acuity care services nationwide.
Amedisys (NASDAQ: AMED) announced the retirement of CEO Paul Kusserow effective April 15, 2022, after seven years in the role. He will remain as Chairman of the Board. Chris Gerard, currently President and COO, will succeed him as CEO. Under Kusserow’s leadership, Amedisys improved its Home Health Quality of Patient Care Star score from 3.5 to 4.33 and expanded its business significantly, increasing market cap from $900 million to over $5.3 billion. The leadership transition is expected to be seamless, with Gerard highlighting growth opportunities ahead.
Amedisys, a leading provider of home health and hospice services, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12 at 3:45 p.m. EST. The presentation will feature key executives including Paul B. Kusserow, Chris Gerard, and Scott Ginn. Interested parties can access the live webcast through the company's website. Amedisys focuses on delivering personalized patient care across various service lines, catering to over 418,000 patients annually. The company has a significant presence, with approximately 21,000 employees and 529 care centers nationwide.
Amedisys, a prominent provider of in-home healthcare, announced key presentations at the Bank of America Securities 2021 Virtual Healthcare Conference. Scheduled for December 6 at 9:00 a.m. Eastern, the presentation will feature Paul B. Kusserow, Chris Gerard, and Scott Ginn. Amedisys specializes in home health, hospice, and personal care services, partnering with over 2,900 hospitals and 78,000 physicians. The company, headquartered in Baton Rouge, serves over 418,000 patients annually, employing around 21,000 staff across 529 care centers in 38 states.
Amedisys, a top provider of home health services, announced its participation in the Stephens Annual Investment Conference on December 3rd at 10:00 AM Eastern. Presenters include Paul B. Kusserow, CEO, Chris Gerard, COO, and Scott Ginn, CFO. The event can be accessed via a live webcast on Amedisys' investor relations website. With over 21,000 employees and 529 care centers nationwide, Amedisys delivers personalized care to over 418,000 patients annually, partnering with more than 2,900 hospitals and 78,000 physicians across the U.S.
Penn State Health has formed a partnership with Highmark Health and Contessa to introduce Home Recovery Care, which includes Hospital and Skilled Nursing Care at Home. This initiative aims to provide essential hospital-level care in patients' homes, enhancing patient comfort while potentially reducing healthcare costs. The model, which has shown a 44% reduction in readmissions and a 35% decrease in hospital stay length, is set to launch at the Milton S. Hershey Medical Center in the first half of 2022, initially for Highmark Medicare Advantage members.
Amedisys, a top provider of home health and hospice services, announced its participation in the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 PM Eastern. Presenters include CEO Paul B. Kusserow, COO Chris Gerard, and CFO Scott Ginn. A live webcast of the presentation will be accessible on their website. Amedisys specializes in personalized home care, catering to patients recovering from surgeries, managing chronic illnesses, and providing hospice care. The company serves over 418,000 patients annually through its extensive network of care centers across the U.S.
Amedisys reported financial results for Q3 2021, with net service revenue rising to $553.5 million, up from $544.1 million in 2020. However, net income dropped to $45.0 million, down from $72.0 million in the previous year. Adjusted EBITDA for the quarter was $72.4 million, a decrease from $75.7 million in 2020. For the nine-month period, net service revenue increased by $134.0 million to $1,654.8 million. The company adjusted its 2021 guidance, expecting net service revenue between $2.200 billion and $2.205 billion.
FAQ
What is the current stock price of Amedisys (AMED)?
What is the market cap of Amedisys (AMED)?
What services does Amedisys Inc. provide?
Where is Amedisys Inc. headquartered?
How many employees does Amedisys have?
What is the scope of Amedisys's operations?
How many patients does Amedisys serve annually?
What recent merger has Amedisys entered into?
What recent technological advancement has Amedisys incorporated?
What was Amedisys's net service revenue for Q1 2024?
How does Amedisys coordinate patient care?
What was the Personal Care segment of Amedisys?
